Clinical Features’ Analysis And Application Valuee Of Fiberoptic Bronchoscopy For Severe Pneumonia In Children

PART I CLINICALFEATURES’ANALYSIS FORSEVERE PNEUMONIA IN CHILDRENObjective: To analyze the etiology and clinical features of pediatricpatients with severe pneumonia.Methods: Retrospective analyze the clinical and etiological featuresof91cases with severe pneumonia hospitalized in the second respiratorydepartment of Children’s hospital affiliated to Chongqing MedicalUniversity in January2013to December2013.Results: Patients’ age distribution:0~1y63cases (69.2%),1~3y17cases (18.7%),3y~11cases (12.1%). Pathogen detection for virus49strains (44.5%)，bacteria45strains (41.0%), other pathogens16strains(14.5%).The main virus infection were ADV (49.0%,24/49)、RSV (26.5%,13/49)；The main bacteria infection were SP (33.3%,15/45)、KP (13.3%,15/45)、E.coli (13.3%,15/45)、HPI (13.3%,15/45). MP (68.8%,11/16)was the main one in other pathogens. Conclusions:(1) Severe pneumonia is peaking at infants andpriority to virus infection.(2) ADV is the most common pathogen ininfants’severe pneumonia, followed by SP、RSV、MP. PART II THE APPLICATION VALUEE OFFIBEROPTIC BRONCHOSCOPY FOR SEVEREPNEUMONIA IN CHILDRENObjective: Explore the application value of fiberoptic bronchoscopefor severe pneumonia in children.Methods:(1) Retrospective analyze the clinical data of91cases withsevere pneumonia hospitalized in the second respiratory department of ourhospital from January to December in2013. Divide the patients intotreatment group (43cases) and control group (48cases) according towhether BAL or not. Compared the outcome﹑hospitalized days andsymptoms controlled time of the two groups after treatment for1weeks.Results: In treatment group:18cases clinical cured,23casesimproved,2cases were invalid, with cured rate41.9%and total effectiverate95.3%; In control group:10cases clinical cured,31cases improved,7 cases were invalid, with cured rate20.8%and total effective rate85.4%.Statistical difference was found between the two groups in treatment effect(P<0.05). In treatment group: cough controlled time were (6.3±3.1) d、wheeze controlled time were (5.3±2.6) d, hospitalization day were(10.0±4.2) d; The matching data in control group were (8.3±3.4) d,(6.9±3.4) d,(12.0±3.6) d. There were significant statistical difference inhospitalized days and symptoms controlled time between the two groupswith P<0.05.Conclusion: BAL could elevate the treatment effect, improve clinicalsymptoms of severe pneumonia significantly and shorten hospitalizedstays.